Views & Analysis Rethinking access barriers to innovation Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs.
Views & Analysis 2021 market access prospects for Germany The market access landscape in Germany is particularly interesting in 2021, as a key component – AMNOG – is ten years old, and that milestone prompts reflections on what has worked well and
Digital Chaos & opportunity: Dr Adam Brown unpacks US health policy Dive into our video interview with Dr Adam Brown as he unpacks the chaos and opportunity shaping US health policy.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
